Whats new

Whats new.

Canaccord Genuity - Headstrong conviction in Efti's potential clinical impact; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

June 28th 2024

For a copy of this research report please contact your Canaccord Genuity advisor